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1. Introduction 
Previous studies on cytochrome b carried in our 
laboratory [l-4] , showed the existence of a dynamic 
control mechanism, operating in mitochondria as well 
as in sonicated submitochondrial particles (ETP,). A 
regulatory group, called ‘Y’ (to distinguish it from ‘X’ 
[3,5,6] participating in the thermodynamic control 
- the variation of the reducibility of cytochrome b), 
controls the rate of reduction of the b-type cyto- 
chromes. It was also shown that cytochrome b 
assumes alternatively one of its two kinetic forms, 
active (bA) or sluggish (bs). Cytochrome b, is favoured 
by oxidized Y, while cytochrome b, predominates 
when Y is reduced [ 1 ] . Redox titration and inhibition 
studies deliniates Y from any recognized components 
of the respiratory system. Y is a comparatively slowly 
reacting component [l] located between the anti- 
mycin and 2-heptyl-4-hydroxyquinoline N-oxide 
(HOQNO) inhibition sites [3] with a midpotential 
higher than that of cytochrome c [2]. 
In the present study we looked for this control 
mechanism in complex (II + III) or complex III, so 
to determine whether the regulatory function is an 
integral part of the respiratory chain. 
2. Materials and methods 
Succinate-cytochrome c reductase (complex II t 
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III) was made of fresh beef-heart mitochondria [7] 
by the method of Yamashita and Racker [8] . The 
cholate was removed by dialyzing for 24 h (4°C) 
against 200 vols of 0.1 M phosphate buffer pH 7.4. 
Complex III was prepared from these particles as 
described by King [9]. 
Durohydroquinone (DQH?) was prepared by 
reducing duroquinone in slightly acidic e$anol(2% 
v/v glacial acetic acid) by aqueous solution of NaBH4; 
the reduction was carried only to 85.90% so as to 
ensure absence of NaBH4. Kinetic analyses was car- 
ried as described before [l] . Protein was determined 
by the Biuret method [lo] . 
3. Results and discussion 
To test the operation of the dynamic control 
mechanism, it is best to compare the kinetics of 
the reduction of cyt. b under the two extreme con- 
ditions, when cyt. b is completely in either the active 
or the sluggish form. For the first case, Y should be 
kept oxidized and for the second case Y is pre-reduced 
Thus, we studied the rate of reduction of cyt. b of 
complex (II + III) or complex III, in presence of . 
antimycin (plus 02) or after pretreatment with ascor- 
bate plus NNN‘N-tetramethy p-phenylendiamine 
(TMPD). 
The succinate cytochrome c reductase preparation 
contained cytochrome b and cl 1.5 and 0.9 nmol/mg 
respectively, with specific activity (measured accord- 
ing to Tisdal [l 11) of 0.34 pmol min -I X mg-’ at 
room temperature. Similar values were obtained by 
other groups [ 121. The cyt. c reduction was complete- 
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ly blocked by antimycin (0.36 nmol/mg) or by 
HOQNO (13.4 PM). No spectral evidence for cyt. c or 
a + a3 was observed. Yet, by addition of KCN (2 mM) 
the rate of reduction of external cyt. c was slightly 
enhanced (10%) and the amount cyt. cr aerobically 
reduced by succinate, was increased 3-fold. Thus we 
have to conclude that the preparation was not free of 
traces of cytochrome oxidase. It should be empha- 
sized that 3 mM ascorbate plus 50 I.IM TMPD kept 
cyt. cr in a fully reduced state. Thus this treatment 
is justified for reduction of Y. 
Typical results are given in table 1. The first line 
demonstrates that in the presence of antimycin and 
O2 the reduction of cyt. b is rapid and that the rate 
constant (measured at 2°C) is comparable to that 
obtained for submitochondrial particles under similar 
conditions [l] . Pretreatment with ascorbate plus 
TMPD, changed the reduction rate to a value typical 
for cyt. b, [ 1,3]. The same was observed for reduc- 
tion by DQHz. The reduction of cyt. b, is extremely 
rapid, instantanous with respect to our instrumenta- 
tion. The reaction of cyt. b, is slow and easily follow- 
ed at 24°C. Consequently we used the IOO-fold 
difference in the rate of reduction of b, VS. b, by 
DQH? as a diagnostic test for the existence of the 
active and sluggish forms of cyt. b in complex III. 
Complex III: the amount of native cyt. b in com- 
plex III was determined by reduction with NazSz04 
and bleaching the denatured cyt. b by CO [ 131. In 
complex III, only 59% of cyt. b was native, but all of 
the fraction reduced by DQH2 was native. This frac- 
tion, as determined by absorbance spectrum, was 
cyt. bsbl. The rest of cyt. b could be reduced by DQHz 
in a transient way upon addition of K3Fe(CN), 
[5,14,15] . As shown in the third line in table 1 and 
also demonstrated in fig. 1, curve B, the addition of 
DQHz caused an immediate reduction of cyt. b. 
Treatment with ascorbate plus TMPD, brought a slow 
reduction of cyt. b (distinguishing it from complex 
(II t III)) but after this fraction was reduced, addition 
of DQHZ caused a further reduction of cyt. b - in a 
very slow reaction (fig.1, curve A). Thus the ascorbate- 
TMPD treatment did transform b, to b, in isolated 
complex III. 
In order to ascertain the above conclusion we 
looked also for the reversibility of this transition. In 
the submitochondrial particles, the bs -+ b, transi- 
tion was achieved by adding K3Fe(CN), [3]. This 
Table 1 
Kinetic parameters of the reduction of cyt. b in complex (II + III) and complex III. The reduction was followed at 
563-675 nm and the rate constants were calculated as described before [I] 
Batch 
Reagents in the solution 
Experimental conditions 
Antimycin only Antimycin+ascorbate +TMPD 
lac 
2bc 
3ad 
substrate 
Succinate 
(6.7 mM) 
DQH, 
(0.5 mM) 
DQH, 
(0.5 mM) 
complex type temp. “C k(sec-’ ) AA k(sec-’ ) AA 
II + III 2 0.16 0.0135 0.027ef 0.0133 
II + III 24 >>0.6 0.0050 0.010 0.0045 
III 0.5 >>0.6 0.0084 0.004eg 0.0048 
a 0.18 M Sucrose, 50 mM Tris Acetate, 5 mM MgSO, pH 7.4. 
b 0.1 M K phosphate buffer pH 7.4. 
c 1 mg protein/ml. 
d 0.75 mg protein/ml. 
e 3 mM ascorbate. 
f 1.5 mM ascorbate. 
g 50 pM TMPD. 
h 30 MM TMPD. 
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Fig.1. The reversibility of bS + bA transition in complex III. 
(A) Complex III vesicles in 0.18 M sucrose, 5 mM MgSO, 
50 mM Tris acetate pH 7.4, 1 mg protein/ml were treated by 
KCN (2 mM) and antimycin (4 nmol/mg). Ascorbate (300 PM) 
and TMPD (50 PM) were added as indicated, followed by 
DQH, (400 PM) and Na,S,O,. The reaction was carried at 
23°C and followed at 561.5-575 nm. (B) Complex III 
vesicles were treated batchwise by KCN, antimycin ascorbate 
and TMPD as described in (A). After 1 min (23°C) the 
ascorbate was oxidized by titration with K,Fe(CN), till 
blue colour of TMPD reappeared. The vesicles were spun 
down, resuspended in the same buffer, supplemented by 
KCN (2 mM) and antimycin (4 nmol/mg) and the reduction 
by DQH, followed as before. The total reduction by Na,S,O, 
of sample (B) is somewhat smaller compared to (A). This is 
because of some loss in complex III during centrifugation. 
is not in the 
or ETPB to presence of 02, 
b is fully reducible in presence of antimycin [6, 
14,16-181. With complex III, O2 cannot act as an 
oxidant and KaFe(CN), must be used to induce full 
reduction of cyt. bse5 [5,6,14,19]. Consequently, 
addition of K3Fe(CN), in our case will yield a com- 
plex response reflecting both kinetic and thermo- 
dynamic control. To overcome this difficulty, we 
divided the experiment in two steps. Complex III, 
treated with ascorbate plus TMPD to convert it to 
its bs form, (as in fig.lA), was titrated by KaFe(CN)6 
until1 the blue colour of the oxidized TMPD appeared. 
The complex III vesicles were sedimented by centri- 
fugation, and the reduction of cyt. b was measured in 
presence of KCN and antimycin. In this case DQHz 
caused an immediate reduction of cyt. bs6, (tig.1, 
line B) indicating that the sluggish form was reversed 
to the active one. 
It is evident that the control group Y is tightly 
bound to the respiratory carriers and follows the 
b-cl segment of it. Furthermore, the operation of 
the dynamic control in complex III with DQHz as 
reductant eliminates the possibility that the mechanism 
of this control functions via CoQ. Thus the dynamic 
control is not a consequence of some partial reactions 
of the quinone cycle [20]. 
The results described above are in accord with 
Trumpower and Katki [21] , who reported an inhibi- 
tory effect of ascorbate on the reduction of cyt. b 
in succinate cytochrome c reductase particles, a 
phenomenon identical to the dynamic control 
described before [l-4] . We wish to point out 
though qualitatively results are to ours, 
are some discrepencies, especially 
rate of of the form, 0.0005 
in their and 0.027 in this Presently, 
there no explanation this 60-fold but, 
it be due the presence contamination by 
oxidase in preparation. As 
tioned in case the state reduction cyt. c 
succinate was 30% of obtained in 
sence of a control in Trumpower 
Katki experiment. continuous leak electrons to 
might cause major change the observed 
constant of of bs which is inherently 
slow. Being aware of this, 2 mM KCN was present in 
all of our studies. On the other hand its absence in 
the studies of Trumpower and Katki studies might 
lead to underestimation of the rate of reduction of 
4. 
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